Industry · page 2
Pharma & HCP
How patients and healthcare professionals decide: starting, switching and stopping treatments, what cost and coverage do to those decisions, and what doctors weigh that patients never see.
What has Brox published on pharma & hcp?Newest first
-
Adult ADHD with anxiety: the ten US physicians who manage it do not refer, and six treat the anxiety first
6 Not one of the ten physicians who manage this patient refers it straight out. (base 10)
Read -
When a pharmacy closes, 89% would stay with the same chain, and an on-time guarantee holds them better than a discount
89% A store closing moves almost nobody off the chain: 89% (178 of 200) would keep their prescriptions with it. (base 200)
Read -
GLP-1 pill or injection? 37.5% of weekly injection users would switch at the same price, and a smaller weight loss cuts that to 17.0%
37.5% 37.5% of weekly GLP-1 injection users (75 of 200) would be likely to switch to a once-daily pill at the same price and the same weight loss; 55.0% would be very unlikely to. (base 200)
Read -
Medicare Advantage members would stay for their doctors, not a lower price: 12 of 23 name keeping their providers
12 For the Medicare Advantage members on this panel, keeping their own doctors is the one thing that would hold them to their insurer. (base 23)
Read -
Biosimilar substitution: 94.5% of US clinicians, mostly dermatologists, accept a switch they choose, but half object when a pharmacy swaps without contacting them
50% 50.0% of physicians who manage biologics are uncomfortable (1 or 2 of 5) with a pharmacist substituting an interchangeable biosimilar for a stable patient without contacting them first, against 2.7% when they choose the switch and 20.5% when an insurer requires it. (base 146)
Read -
Past GLP-1 users would restart at $99 a month (59.1%), but those who quit over side effects hold out even at a $25 copay
59.1% 59.1% of past GLP-1 users would likely restart within six months at $99 a month out of pocket, against 13.8% at $349 and 72.7% with a $25 insurance copay (base 159)
Read -
GLP-1 considerers: cost holds back 70.8%, and starting only becomes likely near $49 a month
70.8% 70.8% of never-users considering a GLP-1 say the monthly cost is the one concern that most holds them back, far ahead of not being sure it is medically right (13.9%) and side effects (11.7%). (base 137)
Read -
US dermatologists put safety first (40.9%) and patient cost last (2.4%) when choosing a systemic therapy, yet 46.9% say coverage or cost overrode that choice in about half or more of their starts
40.9% Asked which one factor carries the most weight when they choose a systemic agent for moderate-to-severe inflammatory skin disease, 40.9% of US dermatologists name safety and the side-effect profile, 33.1% efficacy in trial data and their own experience, 18.9% whether the patient's insurance will cover it without a fight, 2.4% what the patient asks for and 2.4% what the patient will pay out of pocket; ease of administration (1.6%) and speed of onset (0.8%) trail. (base 127)
Read -
Fear of side effects, not cost, keeps 53.6% of US migraine sufferers on the treatment they have
53.6% 53.6% of US migraine sufferers say worry about the side effects of something new is what would most keep them on their current treatment if a new one were available; 31.8% say what they have works well enough, 6.4% say their doctor has not suggested changing, 4.5% would switch as soon as something better appeared and 3.6% are unsure what a new drug would cost or whether insurance would cover it. (base 110)
Read -
Veridian Oncology, an Invented Biotech: M&A Stress Test
18% peak-share assumption after the patient evidence, down from management's 30% (base 958)
Read -
GLP-1医薬品をDTC型で提供するオンライン診療モデルのSWOT分析
80.4% trust a doctor's recommendation over any other channel (base 528)
Read -
GLP-1 DTC Telehealth — SWOT Analysis
80.4% trust a doctor's recommendation over any other channel (base 528)
Read -
肥満・糖尿病治療薬GLP-1に対する意識調査の詳細分析 | GLP-1 Perception Deep Dive (JP)
900 clones asked how likely they would be to try a GLP-1 at four monthly price points; even free barely moved the needle (base 900)
Read -
Prediktif Fiyat Hassasiyeti Analizi: İlaç | Predictive Price Sensitivity Analysis: Pharma (TR)
7pp point drop in willingness for a severe disease despite a 25x copay increase ($10 to $250) (base 900)
Read -
GLP-1 Derin Algı Analizi | GLP-1 Perception Deep Dive (TR)
900 clones asked how likely they would be to try a GLP-1 at four monthly price points; even free barely moved the needle (base 900)
Read -
製薬分野における価格感度の予測分析 | Predictive Price Sensitivity Analysis: Pharma (JP)
7pp point drop in willingness for a severe disease despite a 25x copay increase ($10 to $250) (base 900)
Read -
GLP-1 Perception Deep Dive
900 clones asked how likely they would be to try a GLP-1 at four monthly price points; even free barely moved the needle (base 900)
Read -
Predictive Price Sensitivity Analysis: Pharma
7pp point drop in willingness for a severe disease despite a 25x copay increase ($10 to $250) (base 900)
Read
Other industries
How should you read these findings?
Where the numbers come from. Every figure on this site is a predicted response from Brox clones: behavioural replicas of real people, each built from a long-form interview with that person. The base under each figure is the number of clones behind it.
Where the real data comes from. The long-form video interviews with the real people the clones are built from. A quote is always shown with the interview line it was predicted from.
What you can take away. Insights publish their tabulation as CSV and JSON: question, option, count, percentage and base. Never per-person rows.
Ask this of your own customers: humans@brox.ai